- Home
- PPBT vs VCIG Comparison
PPBT vs VCIG Comparison
Compare PPBT & VCIG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PPBT
- VCIG
- Stock Information
- Founded
- PPBT 2010
- VCIG 2013
- Country
- PPBT Israel
- VCIG Malaysia
- Employees
- PPBT N/A
- VCIG N/A
- Industry
- PPBT Biotechnology: Pharmaceutical Preparations
- VCIG Diversified Commercial Services
- Sector
- PPBT Health Care
- VCIG Consumer Discretionary
- Exchange
- PPBT Nasdaq
- VCIG Nasdaq
- Market Cap
- PPBT 7.4M
- VCIG 7.5M
- IPO Year
- PPBT N/A
- VCIG 2023
- Fundamental
- Price
- PPBT $0.71
- VCIG $1.15
- Analyst Decision
- PPBT Strong Buy
- VCIG
- Analyst Count
- PPBT 1
- VCIG 0
- Target Price
- PPBT $33.00
- VCIG N/A
- AVG Volume (30 Days)
- PPBT 21.8M
- VCIG 8.8M
- Earning Date
- PPBT 11-14-2025
- VCIG 10-06-2025
- Dividend Yield
- PPBT N/A
- VCIG N/A
- EPS Growth
- PPBT N/A
- VCIG N/A
- EPS
- PPBT N/A
- VCIG 0.98
- Revenue
- PPBT N/A
- VCIG $32,903,041.00
- Revenue This Year
- PPBT N/A
- VCIG N/A
- Revenue Next Year
- PPBT N/A
- VCIG N/A
- P/E Ratio
- PPBT N/A
- VCIG $1.22
- Revenue Growth
- PPBT N/A
- VCIG 24.77
- 52 Week Low
- PPBT $0.53
- VCIG $0.91
- 52 Week High
- PPBT $13.95
- VCIG $4,644.00
- Technical
- Relative Strength Index (RSI)
- PPBT 45.98
- VCIG 35.70
- Support Level
- PPBT $0.71
- VCIG $0.93
- Resistance Level
- PPBT $0.89
- VCIG $2.18
- Average True Range (ATR)
- PPBT 0.13
- VCIG 0.42
- MACD
- PPBT 0.01
- VCIG 0.09
- Stochastic Oscillator
- PPBT 17.37
- VCIG 9.44
About PPBT Purple Biotech Ltd.
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.
About VCIG VCI Global Limited
VCI Global Ltd is a holding company. The principal activities of the Company and its subsidiaries are the provision of business Strategy consultancy and technology development. The firm organized its consulting services into three main segments: Business Strategy Consultancy; Technology development, solutions and consultancy; and Others. It derives the majority of its revenue from the Business Strategy Consultancy segment, which focuses on listing solutions, investor relations, and boardroom strategies consultancy.